

Title

Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Perú

Authors

Christian Chiara Chilet¹

Medalit Luna Vilchez¹

Julio Maquera Afaray¹

Blanca Salazar Mesones¹

Diana Portillo Alvarez¹

Ramiro Priale Miranda¹

Franklin Mendoza¹

Aldo Munayco¹

Jenny Baca²

Mitsi Santiago²

Jose W. López^{1,3}

Affiliations

¹ Unidad de Atención Integral Especializada, Instituto Nacional de Salud del Niño San Borja, Lima, Perú.

² Coordinación técnica de epidemiología, Instituto Nacional de Salud del Niño San Borja, Lima, Perú.

³ Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Perú

Corresponding author

Name: Jose Wagner Lopez Revilla

Address: Carretera Panamericana Sur Km. 19. Villa El Salvador. Lima

Email: jlopezre@cientifica.edu.pe

Telephone: (+51) 610 6400

Author contributions

C.Ch., M.L, J.M., B.S., D.P., R.P., F.M., A.M, and J.W.L conceived the study. C.Ch., M.L, J.M., B.S., D.P., R.P., J.B., M.S. and J.W.L collected the data. C.Ch., J.W.L and M.L performed statistical analysis and figure generation. All authors reviewed the manuscript.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

The study has been funded through the research incentive processes of the *Instituto Nacional de Salud del Niño San Borja*.

Conflicts of interest

The authors declare no conflict of interest

Title:

Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Perú

Abstract

Introduction

The COVID-19 pandemic has a great impact on children's health. This study describes the clinical, epidemiological and treatment characteristics of children presenting COVID-19 at the San Borja National Children's Health Institute in Perú.

Methods

This was a retrospective study of patients with a confirmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological, and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine differences between patients in general wards and the intensive care unit (ICU).

Results

We included 91 patients, 33 being females (36.3%). The most affected age group was children > 2 years of age (63 cases) with a median age of 6 years (IQR 3-10), and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever (39.6%), general malaise (23.1%), cough (19.8%), and respiratory distress (14.3%). The presence of multisystem inflammatory syndrome in children (MIS-C) was confirmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern was bilateral interstitial infiltrates (57.7%). Mortality was higher in patients in the ICU than in the

hospitalization ward (27.3% vs. 4.3%, respectively; $p = 0.02$)

Conclusions

COVID-19 in children presents mild and moderate clinical manifestations. The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care units.

Keywords: COVID-19, children, comorbidity

Introduction

The world is currently facing the largest public health crisis with the new coronavirus pandemic. It has been estimated that more than 90% of the cases correspond to the adult population and only between 1 to 5% occur in the pediatric population(1). Among the latter, more than 90% of cases present asymptomatic, mild or moderate forms of the disease, and only 5.9 % are severe cases (2). This percentage is much lower compared to 18.5% of severe cases reported in the adult population (3).

On the other hand, an association between the presence of comorbidity and severe disease has been reported in a study of 48 pediatric patients admitted to the intensive care unit (ICU), in which 40 children (83%) had some comorbidity (4), and in another study including 651 children, 276 (46%) had at least one comorbidity (6).

The development of pediatric multisystemic inflammatory syndrome (MIS-C) has also been described, which can be severe and present with significant cardiac involvement (5). It has been found that patients with MIS-C were 5 times more likely to be admitted to the ICU (6). In Peru, it has been determined that the incidence of COVID-19 is 10 times higher in adults compared to children (7). However, the behavior of COVID-19 in pediatric patients with and without comorbidities is unknown.

The purpose of this study was to describe the clinical, epidemiological, and treatment characteristics of children hospitalized in our highly complex, specialized, surgical pediatric hospital.

Methods

Study location and design

During the period from March 1st to July 31st, 2020, a retrospective study was conducted to review the medical records of the treated for COVID-19. The INSN-SB is a national pediatric referral center with 306 beds. For the care of patients with COVID-19 24 beds were allocated to confirmed COVID-19 cases and 25 beds to patients suspected of COVID-19 or in need of hospitalization and elective surgery. Twelve beds were allocated to the care of children requiring ICU admission.

Participants

The study included pediatric patients under 18 years of age hospitalized for a laboratory confirmed clinical diagnosis of SARS CoV-2 infection. Patients lacking data of interest in the medical records were excluded. Clinical evaluation was managed by the attending pediatrician according to the institutional care guidelines.

SARS CoV-2 infection was diagnosed by lateral flow immunochromatography in blood or reverse transcription polymerase chain reaction of a nasopharyngeal swab depending on availability. Likewise, as part of the hospitalization criteria, confirmatory laboratory tests were performed in asymptomatic patients before the initiation of chemotherapy or in the preoperative period of elective or emergency surgery. Imaging tests were indicated by the pediatrician and were performed following the guidelines for the care of patients with COVID-19 in the INSN-SB.

Variables of interest

The definition of COVID-19 cases was considered according to the institutional norms of the Peruvian Ministry of Health (8), as well as the definition of the pediatric MIS-C of the World Health Organization (WHO) (9) which includes children and adolescents from 0 to 19 years of age with fever ≥ 3 days in addition to other criteria (9)

The epidemiological variables evaluated were: sex, age, origin by Peruvian department, weight, height, comorbidity, and direct contact with patients with SARS CoV-2 infection. The clinical variables included: date of symptom onset and the presence or absence of symptoms such as general malaise, cough, respiratory distress, diarrhea, abdominal pain, nausea, vomiting, headache, rhinorrhea, pharyngeal pain. The clinical signs considered were: fever, conjunctival injection, rash, dyspnea, snoring, wheezing, crackling, sub-crepitation, seizures, pharyngeal exudate, pretibial edema or desquamation of limbs and tongue swelling.

Laboratory tests for SARS CoV-2 infection included both rapid and molecular tests. Laboratory tests included the determination of hemoglobin, leukocytes, leukocyte formula, platelets, albumin, creatinine, ferritin, C-reactive protein (CRP), procalcitonin, erythrocyte sedimentation rate, lactate dehydrogenase (LDH), alanine-aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, D-dimers, gamma-glutamyl transferase (GGT), and prothrombin time.

Treatment received during COVID-19 infection was based on groups of drugs including antibiotics, antifungals, antivirals, antiparasitics, anticoagulants, antipyretic, human immunoglobulin, corticosteroids, and vasoactive agents.

Finally, the severity of the clinical picture, the need for ICU care, and the date of admission were evaluated, as well as the presence or not of MIS-C. Length of hospital

stay was evaluated considering the final condition of the patient and the cut-off point as July 31st, 2020.

Statistical analysis

The study data were collected and managed using the Integrated Hospital Management System (SIS Galen Plus) (10) and the REDCap electronic data capture tools (11, 12) housed in the INSN-SB.

Descriptive statistics of the variables of interest were first performed, in which the quantitative variables were represented by the median and the interquartile range (IQR), due to the non-normal distribution of the values, and the qualitative variables were analyzed using frequency tables.

Bivariate analysis was then carried out to identify differences between the type of hospitalization (general ward or ICU) with the Chi-square test and Fisher test when appropriate for qualitative variables, while numerical variables were analyzed using non-parametric tests. The statistical analyses were performed using the STATA version 16 program (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC). All differences were considered significant with a p value < 0.05.

Ethical approval

The present study was approved by the Institutional Review Board of the INSN-SB with project code PI-429.

Results

From March 1st to July 31st, 2020, 576 patients suspected of COVID-19 were admitted to the INSN-SB, 19.9% of whom (n = 115) had a diagnosis confirmed by molecular or rapid test. A total of 91 patients were analyzed in the study. The majority of our patients were male; the predominant age group was schoolchildren; 61.5% (n = 56) of the patients came from Lima and 89.1% (n = 81) had incomplete vaccination, 100% of whom (n = 22) were admitted to the pediatric ICU. Table 1 shows the results of the molecular and immunochromatographic tests.

Among the children analyzed, 53.8% (n = 49) had comorbidities, with 68.8% (n = 15) of these children being admitted to the ICU. In 31.2% (n = 15) the most frequent comorbidity was neurological.

The symptoms reported were: general malaise 23.1% (n = 21), cough 19.8% (n = 18), respiratory distress 14.3% (n = 13), vomiting 12.1% (n = 11) as well as clinical signs of fever 39.6% (n = 36), dyspnea 13.2% (n = 12), snoring 9.9% (n = 9) and seizures 5.5% (n = 5).

Most of the patients had a normal chest X-ray (n = 14; 63.6%), with differences being found between children admitted to a hospitalization ward and those admitted to the ICU and having a normal (74% vs. 38.1%, respectively) or abnormal radiographic pattern (26% vs. 61.9%, respectively) (p = 0.01). Furthermore, the most frequent chest radiographic pattern was bilateral interstitial infiltrates in 57.7% (n = 15). (*Supplementary table 1*).

Concerning mortality, differences were observed between children admitted to a hospitalization ward and those admitted to the pediatric ICU (27.3% vs. 4.3%; p =

0.02). Regarding the MIS-C, only 6.6% (n = 6) presented the criteria established by the WHO, with the majority not requiring ICU admission (n = 4)(Table 1).

The results of the laboratory tests upon admission, showed alterations in C-reactive protein (9.4 mg/L; 2.1 - 96.7) and D-dimer levels (0.69 ug/ml; 0.27 - 1.65), while procalcitonin (0.14; 0.05-0.65) and alanine aminotransferase, aspartate aminotransferase and creatinine values were largely unaltered. Concerning the hemogram, most of our patients were not anemic, with hemoglobin values of 11.8 g/dl (9.8 - 12.8). There was also no leukocytosis, neutrophilia, left deviation or marked lymphocytopenia (leukocytes: 10800 x 10³/uL; 7430 - 1450), lymphocytes (3040 x 10³/uL; 1820 -4910), neutrophils (5045 x 10³/uL; 3095-9240) (*Supplementary table 2*).

Regarding coinfection by other pathogens, *Mycoplasma pneumoniae* was the most frequently isolated microorganism by serology (n = 9; 9.9%), followed by cytomegalovirus (n = 3; 3.3%), Epstein Barr virus (n = 2; 2.2%) and influenza (n = 1;1.1%). Gram-positive microorganisms were isolated in 9 cultures (42.9%), with Gram-negative isolates and fungi being detected in a lesser proportion (n = 8; 38.1% and n=4; 19%, respectively).

With regard to medications, 76.9% (n = 70) of the patients received antibiotics, the most frequent being cephalosporins 58.6% (n = 41) and vancomycin 40% (n = 28). Antiparasitic drugs were administered in 25.3% (n = 23) of the patients, with hydroxychloroquine in 17.4% (n = 4). Antipyretics, mainly paracetamol, were also used in 89% (n = 81) of the cases, while 18.7% (n=17) received anticoagulants, 31.9% (n = 29) corticosteroids and 28.6% (n = 26) vasoactive drugs. In relation to MIS-C, 5.5% (n = 5) of patients received human immunoglobulin (*Supplementary table 3*).

Discussion

The majority of patients in this study presented a mild to moderate clinical picture of COVID-19. Almost one third of the patients required admission to the pediatric ICU within the context of associated comorbidities. In addition, a group of patients presented diagnostic criteria of MIS-C, with all evolving favorably.

Similar to what was reported in our study, according to the CDC, the median age of 576 hospitalized children was 8 years (13), and in a systematic review the mean age was 8.9 years (14), with male sex being predominant (13, 14). In addition, the contact was a family member in only one third of our patients (26.4%), unlike other studies which described a history of family contact in more than 40% of cases (14, 15). This finding can be explained by the lack of information on the diagnosis of COVID-19 within the family setting.

Although respiratory symptoms and fever were the most frequent clinical manifestations in our study, 33% of patients presented gastrointestinal symptoms. The presentation of gastrointestinal manifestations in the literature is variable and is currently described in more than 20% of cases (6, 13, 16). Similar to other studies, the most frequent coinfection was *M. pneumoniae* and to a lesser extent with other respiratory viruses (14, 17, 18) In relation to this, it has been described that respiratory viral infections can predispose the development of over-aggregated bacterial infections such as *M. pneumoniae* due to alterations in respiratory mucociliary clearance and immune system response (19). However, *M. pneumoniae* infection can also precede viral infection (20).

Similar to what was reported in our study, one study reported that the most frequent comorbidities were neurological in 11% (65/614) of patients and hematological-

oncological in 8% (45/614) (6). However, in another study the most frequent comorbidity was asthma (12.3%) followed by sickle cell anemia (7%) (19). Many of these comorbidities are related to congenital pathologies unlike in adults. According to severity, one study reported that more than 80% of patients admitted to the ICU presented comorbidities (4).

In our study, we mainly observed an elevation of CRP and D-dimer values, in accordance with what has been found in the literature. Several laboratory abnormalities have been described in COVID-19, especially serum inflammatory markers (6, 14, 22, 23). One study found elevated levels of CRP, procalcitonin, interleukin-6, ferritin, and D-dimers in relation to severity (22). Our findings may be due to the higher proportion of patients with mild and moderate symptoms and because only the initial test results were included in the analysis.

Regarding the cases of MIS-C, in our study 6 patients were diagnosed with MIS-C, and 2 required admission to the pediatric ICU. These results are similar to those described in another Peruvian report in which one eighth of the patients required admission to the pediatric ICU (23). In contrast, in another study MIS-C cases were 5 times more likely to be admitted to the pediatric ICU, with no deaths being reported (6). In both studies the evolution of all the patients was favorable. In contrast, in a systematic review of MIS-C in children and adolescents, MIS-C seemed to be more severe with 68% (531/783) of cases requiring admission to a pediatric ICU (24)

The prescription of antibiotics in the present study was high, although few microbiological findings were of note. One meta-analysis including both adults and children reported that 71.3% were administered antibiotics, despite the prevalence of bacterial co-infections and mild COVID-19 infection as well as 14.3% of secondary

bacterial infection (25). These results suggest that antibiotics should be prescribed under clear clinical suspicion of bacterial infection in patients with COVID-19.

In our study, the use of hydroxychloroquine was infrequent and immunoglobulin was administered mainly in patients with MIS-C criteria. In a systematic review, 7.8% of children received hydroxychloroquine, 4.1% corticosteroids and 3.1% immunoglobulin (14). The low use of hydroxychloroquine can likely be explained by the little scientific evidence initially available, unlike intravenous immunoglobulin which is accepted as immunomodulatory therapy in the management of Kawasaki disease and in MIS-C (6, 23, 26, 27).

Our study has some limitations. One limitation was the absence of complete baseline tests proposed for COVID-19, partly explained by the diversity of clinical criteria for the request. Finally, not all patients diagnosed with MIS-C had undergone a serological test for SARS-CoV 2, and only patients with a positive confirmatory test were included in the present study.

In conclusion, SARS CoV-2 infection in children presents mild and moderate clinical manifestations, with the presence of comorbidities being an important factor for hospitalization, and high mortality upon admission to the pediatric ICU. In addition, patients presenting diagnostic criteria of MIS- C showed a favorable evolution.

Acknowledgments

The authors thank all the INSN-SB Services and Offices for the support and facilities provided during the development of this study.

References

1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. 2020;109(6):1088-95.
2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. 2020;145(6):e20200702.
3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology T.
4. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatrics. 2020.
5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. The Lancet Infectious diseases. 2020:S1473-3099(20)30651-4.
6. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. 2020;370:m3249.
7. MINSA. Situación actual : Brote de COVID-19 en Perú 2020 [Available from: https://www.dge.gob.pe/portal/index.php?option=com_content&view=article&id=67
- 8.

8. Alerta Epidemiológica Codigo: AE-019-2020 [Internet]. 2020. Available from: <https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf>.
9. WHO. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 - Scientific Brief 2020 [Available from: <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>].
10. UNMSM. Gestión en Salud: SIS-GalenPlus 2020 [Available from: <http://gestionensalud.medicina.unmsm.edu.pe/?tool=sis-galenplus>].
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics*. 2009;42(2):377-81.
12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of Biomedical Informatics*. 2019; 95:103208.
13. Wang Y, Zhu F, Wang C, Wu J, Liu J, Chen X, et al. Children Hospitalized With Severe COVID-19 in Wuhan. *The Pediatric Infectious Disease Journal*. 2020;39(7).
14. Kim L WM, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States. *MMWR Morb Mortal Wkly Rep*. March 1–July 25, 2020;1081–1088.

15. Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. *The Journal of pediatrics*. 2020;223:14-9.e2.
16. Foster CE, Moulton EA, Munoz FM, Hulten KG, Versalovic J, Dunn J, et al. Coronavirus Disease 2019 in Children Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes. *Journal of the Pediatric Infectious Diseases Society*. 2020;9(3):373-7.
17. Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MA. Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. *European journal of pediatrics*. 2020;179(7):1079-87.
18. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. *EClinicalMedicine*. 2020;24:100433.
19. Fang F, Luo XP. [Facing the pandemic of 2019 novel coronavirus infections: the pediatric perspectives]. *Zhonghua Er Ke Za Zhi*. 2020;58(2):81-5.
20. Ciofi degli Atti ML, Campana A, Muda AO, Concato C, Ravà L, Ricotta L, et al. Facing SARS-CoV-2 Pandemic at a COVID-19 Regional Children's Hospital in Italy. 2020;39(9):e221-e5.

21. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspá M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health*. 2020;4(9):653-61.
22. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. *PLOS Medicine*. 2020;17(6):e1003130.
23. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. *Pediatrics*. 2020;146(1).
24. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA pediatrics*. 2020:e202430-e.
25. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020.
26. Shelmerdine SC, Lovrenski J, Caro-Domínguez P, Toso S, Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging T. Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings. *Pediatr Radiol*. 2020;50(9):1217-30.

Tables

Table 1. Demographic characteristics of the patients with COVID-19 treated at the Instituto Nacional de Salud del Niño San Borja (n = 91).

Characteristics	Total		General ward		ICU		p value
	n	%	n=69	%	n=22	%	
Sex							0.3
Female	33	36.3	23	33.3	10	45.5	
Male	58	63.7	46	66.7	12	54.5	
Age (median, IQR)							0.6
Neonates (n=2)	13,5		8		19		-
Infants (n=26)	9 (4-17)		9 (4-17)		9 (1-15)		0.6
Children (n=63)	6 (3-10)		6 (3-10)		7.5 (3-11)		0.6
Region							0.2
Lima	56	61.5	45	65.2	11	50	
Province	35	38.5	24	34.8	11	50	
Incomplete vaccination	81	89.1	59	85.5	22	100	0.053
Admission due to surgery							0.1
Emergency	21	53.8	18	60	3	33.3	
Elective	18	46.2	12	40	6	66.7	
Contact							0.2
Family	24	26.4	21	30.4	3	13.6	
Patient	4	4.4	3	4.4	1	4.6	
Unknown	63	69.2	45	65.2	18	81.8	
Diagnostic test							0.15
Immunochromatography	45	49.4	37	53.7	8	36.4	
Molecular assay	46	50.6	32	46.3	14	63.6	
Chest X-ray							0.01
Normal	45	63.4	37	74	8	38.1	
Abnormal	26	36.6	13	26	13	61.9	
Comorbidity							0.1
Yes	49	53.8	34	49.3	15	68.2	
No	42	46.2	35	50.7	7	31.8	
Type of comorbidity							
Neurological	15	31.2					
Cardiology	12	25.5					
Hematology	7	14.9					
Oncologic	7	14.9					
Gastrointestinal	6	12.2					
Trauma	4	7.7					
Pneumology	4	7.7					

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Burns	3	5.77					
Other	2	3.8					
Presence of MIS-C							0.6
Yes	6	6.6	4	5.8	2	9.1	
No	85	93.4	65	94.2	20	90.9	
Final state							0.02
Survivor	82	90.1	66	95.6	16	72.7	
Non-survivor	9	9.9	3	4.4	6	27.3	

IQR: interquartile range

Figure 1. Flow diagram of the selection of patients with COVID-19 in the Instituto Nacional de Salud del Niño San Borja during the period from March 1st to July 31st, 2020.

